Pharma Faces New Foe In Qui Tam Suits; California Insurance Commissioner Intervenes In BMS Case
This article was originally published in The Pink Sheet Daily
The suit, which has been under seal since 2007, alleges Bristol-Myers Squibb offered kickbacks, including a basketball camp with the Los Angeles Lakers, to encourage physicians to prescribe its drugs.
You may also be interested in...
Allergen will pay $600 million for promoting the drug for headache and spasticity; government says company taught physicians how to bill for off-label uses.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.